Non-oral postmenopausal HT is less hazardous to cardiovascular health

Article

Compared with oral formulations, transdermal and intranasal forms of postmenopausal HT produce smaller changes in levels of the cardiovascular risk markers. . .

Compared with oral formulations, transdermal and intranasal forms of postmenopausal hormone therapy (HT) produce substantially smaller changes, if any, in levels of the cardiovascular risk markers, C-reactive protein (CRP) and activated protein C (APCr), suggesting that they pose less of a threat of atherosclerotic and venous thromboembolic disease.

The finding comes from a systematic review of 72 randomized clinical trials. The authors of the review also noted that changes in cell adhesion molecules and some fibrinolytic parameters tended to be smaller with non-oral treatment than with oral HT, whereas changes in lipoprotein(a) and homocysteine did not differ between oral and non-oral forms of therapy. There were also minor or no differences between formulations in their effect on coagulation parameters.

Hemelaar M, van der Mooren MJ, Rad M, et al. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil Steril. 2008;90:642-668.

Recent Videos
The significance of the Supreme Court upholding mifepristone access | Image Credit: unchealth.org
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
raanan meyer, md
© 2024 MJH Life Sciences

All rights reserved.